We searched Embase, Medline, Ovid, and PubMed, with no restrictions on language or dates. We used the search terms “porphyria” and “genotype”, in combination with “phenotype”, “drugs”, “precipitating factors”, “pathogenesis”, “neuropathy”, “symptoms”, “pharmacogenetics”, “CYP450”, “gene therapy”, “mouse model”, “treatment”, “iron metabolism”, and “haem” plus “enzymes”. We largely selected publications from the past 5 years, but did not exclude commonly referenced and highly regarded older
SeminarPorphyrias
Introduction
Porphyrias are a group of eight panethnic inherited metabolic disorders of haem biosynthesis. Each results from a specific enzymatic alteration in the haem biosynthesis pathway (figure 1). Specific patterns of accumulation of the haem precursors 5-aminolaevulinic acid, porphobilinogen, and porphyrins are associated with characteristic clinical features—acute neurovisceral attacks, skin lesions, or both.1, 2 Eight enzymes bring about haem synthesis from glycine and succinyl CoA. The biosynthetic pathway begins in the mitochondria and, after three cytoplasmic stages, the final steps of haem formation take place in the mitochondria (figure 1).
Although haem is synthesised in every human cell for respiratory and oxidation-reduction reactions, it is mostly produced in the erythropoietic cells for haemoglobin synthesis and the liver parenchymal cells for synthesis of cytochromes and haemoproteins. Control of haem production differs between these two tissues, mostly because of differences in rates of synthesis of 5-aminolaevulinic acid. The first enzyme, 5-aminolaevulinic acid synthase (ALAS), is coded by two genes3—one erythroid specific (ALAS2 on chromosome X) and one ubiquitous (ALAS1 on chromosome 3). ALAS1 is the rate-limiting enzyme in the production of haem in the liver and is controlled via negative-feedback regulation by the intracellular uncommitted haem pool4, 5 (figure 2).
In erythroid cells, synthesis of haem is regulated during erythroid differentiation in response to erythropoietin. In these cells, ALAS2 synthesis is induced only during active haem synthesis. The rate is limited by iron availability and is not inhibited by haem.6 Spleen and liver macrophages degrade haem and recycle iron after erythrophagocytosis through inducible haem oxygenase 1 (figure 2). Porphyrias are often classified as hepatic or erythropoietic according to the organ in which haem precursors accumulate (figure 1). However, a classification as acute porphyrias, cutaneous porphyrias, and rare recessive porphyrias based on clinical presentation is directly related to a simple biological diagnosis strategy and is more practical than are other classifications (figure 3).
Section snippets
Presentation
People with autosomal-dominant acute porphyrias—acute intermittent porphyria, variegate porphyria, and hereditary coproporphyria—can present with a sudden life-threatening crisis. These attacks are infrequent because penetrance is low and they are difficult to diagnose because they are non-specific. Acute attacks happen in all acute porphyrias. Skin lesions never develop in acute intermittent porphyria but are the only clinical manifestation in some patients with variegate porphyria (60% of
Bullous porphyrias
Variegate porphyria, hereditary coproporphyria, and porphyria cutanea tarda share the same chronic cutaneous photosensitivity. Porphyria cutanea tarda is the most frequent type of porphyria worldwide and presents with skin symptoms only. Variegate porphyria and hereditary coproporphyria can present with either cutaneous or neuropsychiatric symptoms (figure 4). Laboratory diagnosis is essential to avoid misclassification and unexpected acute attacks (figure 3 and table 1). Lesions are restricted
Congenital erythropoietic porphyria
Congenital erythropoietic porphyria (or Günther disease) is the most frequent of the rare recessive porphyrias. Inheritance is autosomal recessive, and the disorder results from a pronounced deficiency of uroporphyrinogen III synthase enzymatic activity (UROS). The enzymatic defect causes specific overproduction and excretion of the non-physiological and pathogenic isomer I of uroporphyrin and coproporphyrin (Figure 1, Figure 3).115 Molecular study116, 117 of the UROS gene in these patients has
European porphyria network
The European Porphyria Network (EPNET) is a collaborative project between European porphyria centres that was established to provide improved health care for patients and their families. It has been partly funded by the EU Commission Public Health Executive Agency (PHEA). The overall aim is to develop a common approach to diagnosis and clinical management of porphyrias so that patients, their families, and health-care professionals can benefit from access to evidence-based, consensus-agreed
Search strategy and selection criteria
References (140)
- et al.
Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome
Genomics
(1990) - et al.
Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR)
J Biol Chem
(2002) - et al.
Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias
Clin Chim Acta
(1984) - et al.
Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins
Clin Chim Acta
(1995) - et al.
Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients
Clin Biochem
(2000) - et al.
Biochemical differentiation of the porphyrias
Clin Biochem
(1999) - et al.
Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria
Am J Hum Genet
(1997) - et al.
Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation
Am J Hum Genet
(1999) - et al.
Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria
Am J Hum Genet
(2001) - et al.
Liver transplantation as a cure for acute intermittent porphyria
Lancet
(2004)
Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha
Cell
Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1
J Mol Biol
Can pregnancy stop cyclical attacks of porphyria?
Am J Med
Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors
J Hepatol
Familial and sporadic porphyria cutanea: two different diseases
Int J Biochem
Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda
Blood
Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis
J Hepatol
Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda
Lancet
The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda
Hepatology
Down-regulation of hepcidin in porphyria cutanea tarda
Blood
Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review
J Am Acad Dermatol
Effects of chloroquine in hematoporphyrin-treated animals
Chem Biol Interact
Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload
J Dermatol Sci
Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria
Blood
Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice
Blood
Hepatobiliary implications and complications in protoporphyria, a 20-year study
Clin Biochem
Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria
Am J Hum Genet
Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria
Am J Hum Genet
Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias
Disorders of porphyrin metabolism
(Far) Outside the box: genomic approach to acute porphyria
Physiol Res
Translational control of erythroid delta-aminolevulinate synthase in immature human erythroid cells by heme
Cell Mol Biol (Noisy-le-grand)
Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients
Hum Hered
Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene
Clin Genet
A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria
Nat Genet
Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study
Scand J Clin Lab Invest
Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden
J Intern Med
Early administration of heme arginate for acute porphyric attacks
Arch Intern Med
The little imitator–porphyria: a neuropsychiatric disorder
J Neurol Neurosurg Psychiatry
An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity
Medicine (Baltimore)
Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families
Clin Chem
Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria
Clin Chem
Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard
Clin Chem
Hereditary coproporphyria: comparison of molecular and biochemical investigations in a large family
J Inherit Metab Dis
Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update
Hum Mutat
Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase
Eur J Clin Invest
Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene
Clin Chem
Acute porphyrias: pathogenesis of neurological manifestations
Semin Liver Dis
Experimental porphyric neuropathy: a preliminary report
Can J Neurol Sci
Identification of the xenosensors regulating human 5-aminolevulinate synthase
Proc Natl Acad Sci USA
Cited by (577)
Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
2024, Pharmacological ResearchManagement of erythropoietic protoporphyria with cholestatic liver disease: A case report
2023, Molecular Genetics and Metabolism ReportsAcute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples
2023, Molecular Genetics and Metabolism